Pharmaceuticals, Biotechnology and Life Sciences
DUBLIN–(BUSINESS WIRE)–The “Nexagon – Emerging Insights and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
Nexagon is a natural, unmodified oligonucleotide (30-mer) that downregulates expression of the key gap ju…
DUBLIN–(BUSINESS WIRE)–The “Nexagon – Emerging Insights and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
Nexagon is a natural, unmodified oligonucleotide (30-mer) that downregulates expression of the key gap ju…
DUBLIN–(BUSINESS WIRE)–The “Nexagon – Emerging Insights and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
Nexagon is a natural, unmodified oligonucleotide (30-mer) that downregulates expression of the key gap ju…
MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel recombinant proteins in the treatments for neurological and kidney diseases, today announced it will be presenting a p…
MINNEAPOLIS–(BUSINESS WIRE)–DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel recombinant proteins in the treatments for neurological and kidney diseases, today announced it will be presenting a p…
DUBLIN–(BUSINESS WIRE)–The “Pimavanserin – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about an investigational product for major depressive dis…
DUBLIN–(BUSINESS WIRE)–The “Pimavanserin – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about an investigational product for major depressive dis…
DUBLIN–(BUSINESS WIRE)–The “HTD 1801 – Emerging Insight and Market Forecast – 2030” report has been added to ResearchAndMarkets.com’s offering.
HTD1801, is a first-in-class new molecular entity, currently in Phase II trials for the treatment of prim…
Preeminent biotechnology commercialization leader with over 33 years of industry experience, including 16 years at Genentech with a pivotal role in commercializing products across multiple therapeutic areas
GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Th…
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a f…